Get the Stockscreener App
1.6295
3.02%
-0.0305
Milestone Pharmaceuticals Inc stock is currently priced at $1.6295, with a 24-hour trading volume of 120.02K.
It has seen a -3.02% decreased in the last 24 hours and a -6.94% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.67 pivot point. If it approaches the $1.60 support level, significant changes may occur.
Previous Close:
$1.66
Open:
$1.66
24h Volume:
120.02K
Market Cap:
$88.23M
Revenue:
-
Net Income/Loss:
$-59.25M
P/E Ratio:
-1.1894
EPS:
-1.37
Net Cash Flow:
$-49.68M
1W Performance:
-1.23%
1M Performance:
-6.94%
6M Performance:
-33.20%
1Y Performance:
-57.75%
1D Range:
$1.60
$1.6764
52W Range:
$1.33
$4.49
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
514-336-0444
Address
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, QC
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
GlobeNewswire Inc.
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
GlobeNewswire Inc.
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
GlobeNewswire Inc.
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
GlobeNewswire Inc.
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
GlobeNewswire Inc.
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Milestone Pharmaceuticals Inc (MIST) Net Income 2024
MIST net income (TTM) was -$59.25 million for the quarter ending September 30, 2023, a +4.58% increase year-over-year.
Milestone Pharmaceuticals Inc (MIST) Cash Flow 2024
MIST recorded a free cash flow (TTM) of -$49.68 million for the quarter ending September 30, 2023, a +4.73% increase year-over-year.
Milestone Pharmaceuticals Inc (MIST) Earnings per Share 2024
MIST earnings per share (TTM) was -$1.38 for the quarter ending September 30, 2023, a +5.48% growth year-over-year.
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker that has completed Phase II clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating atrial fibrillation and angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
8.71%
3.48%
Cap:
|
Volume (24h):